SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
WOLLAEGER TIMOTHY

(Last) (First) (Middle)
C/O CHIMERIX, INC.
2505 MERIDIAN PARKWAY, SUITE 340

(Street)
DURHAM NC 27713

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHIMERIX INC [ CMRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/03/2014
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/01/2016 P 10,000 A $4.61(1) 10,000 D
Commnon Stock 10/03/2014 G V 57 D $0.00 101 I See Footnote(2)
Common Stock 10/03/2014 G V 101 D $0.00 0 I See Footnote(2)
Common Stock 10/03/2014 G V 101 A $0.00 8,702 I See Footnote(3)
Common Stock 3,311,400 I See attached Exhibit 99.1
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The range of purchase prices paid is $4.58 to $4.65. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
2. The shares are held of record by Kingsbury Associates, LP.
3. The shares are held of record by the Timothy J & Cynthia K Wollaeger Trust.
Remarks:
/s/ Michael Alrutz, Attorney-in-Fact 03/02/2016
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 99.1

The shares of Common Stock are held as follows: 829,046 shares of common stock
held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held
by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by
Sanderling V Limited Partnership, 138,046 shares of common stock held by
Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by
Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock
held by Sanderling Venture Partners V Co-Investment Fund, L.P., 891,189 shares
of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively,
the Sanderling V Shares), 498,046 shares of common stock held by Sanderling
Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held
by Sanderling VI Beteiligungs GmbH & Co. KG, 18,384 shares of common stock held
by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares),
3,446 shares of common stock held by Middleton-McNeil Retirement Trust. Timothy
J. Wollaeger, one of the Issuer's directors, Fred A. Middleton, Robert G. McNeil
and Timothy C. Mills share voting and investment power with respect to the
Sanderling V Shares. Robert G. McNeil, Fred A. Middleton, Timothy C. Mills and

Timothy J. Wollaeger share voting and investment power with respect to the
Sanderling VI Shares. Fred A. Middleton and Robert G. McNeil share voting and
investment power with respect to the shares held by the Middleton-McNeil
Retirement Trust. Each of these individuals disclaims beneficial ownership of
such securities, except to the extent of his or her pecuniary interest therein.